Safety of omalizumab in chronic urticaria during pregnancy: a real-life study
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llad386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Cataldo Patruno und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Chronic Urticaria, Urticaria. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Managing a pregnant patient with chronic spontaneous urticaria (CSU) is often challenging. Recent data have shown that most CSU treatments in pregnant patients are second-generation H1 antihistamines (sgAHs), while data on the safety of omalizumab are scant.
Objectives
To evaluate, in a routine clinical practice setting, the efficacy and safety of omalizumab in patients with severe CSU refractory to sgAHs who either became pregnant during treatment or who started the drug during pregnancy.
Methods
We conducted a retrospective study of women aged ≥ 18 years who were pregnant, who received one or more doses of omalizumab at any time during their pregnancy or who were taking omalizumab at the time of, or in the 8 weeks before, conception.
Results
Twenty-nine pregnant patients were evaluated: 23 (79%) conceived a child while taking omalizumab (group A), while 6 (21%) started omalizumab treatment during pregnancy (group B). Among patients in group A, we observed 23 births (21 liveborn singletons and 1 liveborn twin pair) and 1 miscarriage. Fifteen (65%) patients discontinued omalizumab after confirming their pregnancy, while eight (35%) were exposed to omalizumab during their entire pregnancy. In group B, omalizumab was introduced at a mean (SD) 10.83 (3.60) weeks’ gestation and all patients were exposed to it until the end of pregnancy. In this group, there were seven liveborn infants (five singletons and one twin pair). No adverse events, pregnancy complications or congenital anomalies in newborns were recorded in either group.
Conclusions
Omalizumab for CSU treatment before and during pregnancy does not appear to have negative effects on maternal or fetal outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
- Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Policlinico di Bari, Bari, Italy.
- Dermatology Unit, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
ORCID-Profile: Flavia Raia
Zitieren
APA
Patruno, C., Guarneri, F., Nettis, E., Bonzano, L., Filippi, F., Ribero, S., Foti, C., Rubegni, P., Balato, A., Miniello, A., Motolese, A., Piraccini, B. M., Quaglino, P., Romita, P., Lazzeri, L., Buononato, D., Dastoli, S., Raia, F., & Napolitano, M. (2024). Safety of omalizumab in chronic urticaria during pregnancy: a real-life study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad386
Vancouver
Patruno C, Guarneri F, Nettis E, Bonzano L, Filippi F, Ribero S, et al. Safety of omalizumab in chronic urticaria during pregnancy: a real-life study. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llad386
BibTeX
@article{Patruno2024,
author = {Patruno, Cataldo and Guarneri, Fabrizio and Nettis, Eustachio and Bonzano, Laura and Filippi, Federica and Ribero, Simone and Foti, Caterina and Rubegni, Pietro and Balato, Anna and Miniello, Andrea and Motolese, Alfonso and Piraccini, Bianca Maria and Quaglino, Pietro and Romita, Paolo and Lazzeri, Laura and Buononato, Dario and Dastoli, Stefano and Raia, Flavia and Napolitano, Maddalena},
title = {Safety of omalizumab in chronic urticaria during pregnancy: a real-life study},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llad386}
}
EUVIMED